版本:
中国

BRIEF-Cempra reports anti-nash effects of Solithromycin interim results from phase 2 study

Sept 29 Cempra Inc :

* Nash effects of solithromycin: interim results from phase 2 study

* Cempra Inc says all six patients showed alt reductions after 90 days of treatment with Solithromycin

* Cempra Inc says pre/post treatment biopsies confirm mean nas reduction of 1.3 points after 90 days of treatment with solithromycin

* Cempra inc says Solithromycin was well tolerated Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐